SAG
SAG (CAS 912545-86-9) is a synthetic small-molecule agonist targeting the Smoothened (SMO) receptor, a GPCR-like protein central to the Hedgehog (Hh) signaling pathway. It activates SMO with an EC50 of approximately 3 nM, thus stimulating downstream Gli transcription factor activity involved in embryonic development and adult tissue homeostasis. At concentrations above 1 μM, SAG exhibits inhibitory effects on pathway signaling. It binds directly to SMO, forming an interaction with a reported dissociation constant (K_D) around 59 nM. SAG is employed in biomedical research, notably to mitigate glucocorticoid-induced cerebellar injury in primary mouse neuronal cell cultures.
| Storage | Store at -20°C |
| M.Wt | 490.06 |
| Cas No. | 912545-86-9 |
| Formula | C28H28ClN3OS |
| Solubility | ≥24.5 mg/mL in DMSO; ≥16.33 mg/mL in H2O with gentle warming and ultrasonic; ≥2.61 mg/mL in EtOH with gentle warming and ultrasonic |
| Chemical Name | 3-chloro-N-((1r,4r)-4-(methylamino)cyclohexyl)-N-(3-(pyridin-4-yl)benzyl)benzo[b]thiophene-2-carboxamide |
| SDF | Download SDF |
| Canonical SMILES | CN[C@@]1([H])CC[C@@](N(C(C2=C(Cl)C3=CC=CC=C3S2)=O)CC4=CC(C5=CC=NC=C5)=CC=C4)([H])CC1 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
Shh-LIGHT2 cell line |
|
Preparation method |
The solubility of this compound in DMSO is >24.5mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.1~100 μM |
|
Applications |
SAG induces Hh pathway activation in a mouse cultured cell with an EC50 of ~3 nM, however, the pathway activity decreases dramatically as SAG concentration surpasses 1 μM. |
| Animal experiment [2]: | |
|
Animal models |
P4 wild-type mice |
|
Dosage form |
SAG (20 μg/g) with prednisolone (0.67 μg/g), daily, 7 days |
|
Application |
SAG at the treatment dose effectively prevented glucocorticoids-induced neonatal cerebellar developmental abnormalities in the mouse. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Chen JK, Taipale J, Young KE et al. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6. [2] Heine VM, Griveau A, Chapin C et al. A small-molecule smoothened agonist prevents glucocorticoid-induced neonatal cerebellar injury. Sci Transl Med. 2011 Oct 19;3(105):105ra104. | |
Quality Control & MSDS
- View current batch:
Chemical structure
